Neoplasm: Clinical Trials

13 trials for Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Completed 13
Phase 14Completed 4

Follow Neoplasm: new trials by email Literature Review of Neoplasm trials Research Report on Neoplasm

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Erdafitinib - Neoplasm
Phase 2CompletedJanssen Research & Development, LLC352016-07-082025-04-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma
Phase 1 / Phase 2CompletedCelgene1072013-12-042019-12-27
Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)
Pegylated Recombinant Human Arginase I - Neoplasm, Hepatocellular Carcinoma
Phase 1 / Phase 2CompletedBio-Cancer Treatment International Limited202010-03-012012-03-14
Study of ADI-PEG 20 in Patients With Advanced Melanoma
ADI PEG 20 - Metastatic Melanoma, Skin Cancer
Phase 1 / Phase 2CompletedLudwig Institute for Cancer Research312007-07-012022-10-25
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
MK2461 - Neoplasm
Phase 1 / Phase 2CompletedMerck Sharp & Dohme LLC262007-06-012015-03-31
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
PTK787/ZK222584 - Neoplasm
Phase 2CompletedPancreatic Cancer Research Team672005-12-012012-05-09
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
cetuximab - Colorectal Neoplasms, Metastases
Phase 2CompletedEli Lilly and Company872004-10-012011-05-25
Extension Program for Bay 43-9006
Nexavar (Sorafenib, BAY43-9006) - Neoplasm, Metastasis
Phase 2CompletedBayer92002-12-012014-12-23
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
Karenitecin (BNP1350) - Melanoma, Neoplasm
Phase 2CompletedBioNumerik Pharmaceuticals, Inc.462002-05-012020-03-12
A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning
Radiotherapy - Neoplasm
Phase 2CompletedNational Cancer Institute (NCI)1401999-05-012008-03-04
Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
Gamma-camera imaging, Low-risk biopsy - Neoplasm
Phase 2CompletedNational Cancer Institute (NCI)1001997-12-012008-03-04
Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts
collaboration - Neoplasm
Phase 2CompletedNational Cancer Institute (NCI)1001994-10-012008-03-04
Effectiveness of the FairCare System for Patients With Advanced Illness
End of life care coordination, FairCare System - Terminal Care, Neoplasm
Phase 2CompletedUS Department of Veterans Affairs1402015-04-07

Narrower conditions

Neoplasms (13)  ·  Melanoma (3)  ·  Neoplasm Metastasis (3)  ·  Acrocephalosyndactylia (1)  ·  Adenocarcinoma (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Dermatofibrosarcoma (1)  ·  Esophageal Neoplasms (1)  ·  Fibrosarcoma (1)  ·  Histiocytoma (1)  ·  Leukemia (1)

Broader conditions

Neoplasms by Histologic Type (7)  ·  Neoplasms by Site (7)  ·  Neoplasms, Glandular and Epithelial (4)  ·  Skin Diseases (4)  ·  Skin and Connective Tissue Diseases (4)  ·  Carcinoma (3)  ·  Digestive System Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Neoplastic Processes (3)  ·  Neuroectodermal Tumors (3)  ·  Neuroendocrine Tumors (3)  ·  Nevi and Melanomas (3)  ·  Pathologic Processes (3)

Interventions

130-nm albumin-bound paclitaxel (1)  ·  5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one (1)  ·  ADI PEG20 (1)  ·  Albumin-Bound Paclitaxel (1)  ·  BCT-100 (1)  ·  Bevacizumab (1)  ·  Cetuximab (1)  ·  Intersectoral Collaboration (1)  ·  Radiotherapy (1)  ·  Sorafenib (1)  ·  cositecan (1)  ·  erdafitinib (1)  ·  vatalanib (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Bayer (1)  ·  Bio-Cancer Treatment International Limited (1)  ·  BioNumerik Pharmaceuticals, Inc. (1)  ·  Celgene (1)  ·  Eli Lilly and Company (1)  ·  Janssen Research & Development, LLC (1)  ·  Ludwig Institute for Cancer Research (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Pancreatic Cancer Research Team (1)  ·  US Department of Veterans Affairs (1)

Countries

United States (10)  ·  Canada (3)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  South Korea (1)  ·  Spain (1)  ·  Switzerland (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Anna Pavlick, DO (1)  ·  Gary Schwartz, MD (1)  ·  Ileana Elias, M.D. (1)  ·  Jedd Wolchok, MD, PhD (1)  ·  Mollie Shulan, MD (1)  ·  Ronnie TP Poon, Prof (1)  ·  Tomislav Dragovich, MD, PhD (1)

Results publications

PMID 22864522, PMID 31401903, PMID 32554315, PMID 33856599, PMID 39138436